Nykode Therapeutics - Annual Report 2022

19 Apr 2023 08:00 CEST

Oslo, Norway, April 19, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced the publication of the
Annual Report and ESG Report for 2022.

The Board of Directors of Nykode Therapeutics ASA has approved the annual
accounts for 2022. The financial statements and annual report for the financial
year 2022 are, together with the ESG report, attached to this announcement. The
ESEF file is also attached.

The documents are available in the investors section of the Company’s website:
https://nykode.com/investors/financial-reports-and-presentations/


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode’s modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen
vaccine, which is exclusively out-licensed to Genentech, a member of the Roche
Group. Additionally, Nykode is conducting a Phase 1/2 trial with next-generation
COVID19 vaccine candidates.

The Company’s partnerships include Genentech within oncology, a multi-target
collaboration with Regeneron within oncology and infectious diseases and a
collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine
development.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics may be found at
http://www.nykode.com.


Contact for Nykode Therapeutics ASA:
Chief Business Officer, Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

587901_nykode-2022-12-31-en.zip
587901_Nykode Annual Report 2022.pdf
587901_Nykode ESG Report 2022.pdf